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********Division of Gastroenterology and Hepatology, Stanford University, Stanford, CaliforniaBACKGROUND & AIMS: Direct-acting antivirals (DAAs) are effective against hepatitis C virus and sustained virologic
response is associated with reduced incidence of hepatocellular carcinoma (HCC). However,
there is controversy over the use of DAAs in patients with active or treated HCC and uncer-
tainty about optimal management of these patients. We aimed to characterize attitudes and
practice patterns of hepatology practitioners in the United States regarding the use of DAAs in
patients with HCC.METHODS: We conducted a survey of hepatology providers at 47 tertiary care centers in 25 states. Surveys
were sent to 476 providers and we received 279 responses (58.6%).RESULTS: Provider beliefs about risk of HCC recurrence after DAA therapy varied: 48% responded that
DAAs reduce risk, 36% responded that DAAs do not change risk, and 16% responded that
DAAs increase risk of HCC recurrence. However, most providers believed DAAs to be beneficial
to and reduce mortality of patients with complete response to HCC treatment. Accordingly,
nearly all providers (94.9%) reported recommending DAA therapy to patients with early-
stage HCC who received curative treatment. However, fewer providers recommended DAA
therapy for patients with intermediate (72.9%) or advanced (57.5%) HCC undergoing palli-
ative therapies. Timing of DAA initiation varied among providers based on HCC treatment
modality: 49.1% of providers reported they would initiate DAA therapy within 3 months of
surgical resection whereas 45.9% and 5.0% would delay DAA initiation for 3–12 months and
>1 year post-surgery, respectively. For patients undergoing transarterial chemoembolization
(TACE), 42.0% of providers would provide DAAs within 3 months of the procedure, 46.7%
would delay DAAs until 3–12 months afterward, and 11.3% would delay DAAs more than 1
year after TACE.CONCLUSIONS: Based on a survey sent to hepatology providers, there is variation in provider attitudes and
practice patterns regarding use and timing of DAAs for patients with HCC. Further studies are
needed to characterize the risks and benefits of DAA therapy in this patient population.Keywords: Liver Cancer; HCV; TACE; Drug.Hepatocellular carcinoma (HCC) is the fastestrising cause of cancer-related death in the
United States, with most cases attributed to chronic
hepatitis C virus (HCV) infection.1–3 Highly effective
direct-acting antivirals (DAAs) have revolutionized
HCV treatment, resulting in high rates of sustained viro-
logic response (SVR). HCV eradication in patients with
cirrhosis with DAAs is cost-effective4 and has several
benefits including reduced risk of hepatic decompensa-
tion,5 improvement in all-cause mortality,6,7 and
decreased incident HCC.7–9
However, the effect of DAAs on risk of tumor
recurrence in patients with a history of treated HCC
remains controversial after an observational study
from Spain found a higher-than-expected proportion of
patients with HCC recurrence after DAA treatment.10
Subsequent studies have produced conflicting data,
including a large multicenter study showing no signif-
icant difference in early HCC recurrence, overall
recurrence, or tumor aggressiveness between DAA-
treated and untreated patients.11 Furthermore, there
are unknown benefits of DAA treatment in patientswith active HCC, particularly in light of reports
showing reduced rates of SVR.12,13
While awaiting prospective data, there remains un-
certainty about the optimal management of patients with
HCV and HCC, which may lead to confusion among pro-
viders. To our knowledge, provider attitudes and prac-
tice patterns in this patient population have not been
assessed. Therefore, we conducted a nationwide survey
study to evaluate attitudes and practice patterns of US
hepatology practitioners regarding the use and timing of
DAA treatment in patients with HCC.Methods
Participants
We conducted a survey among hepatology providers
at 47 tertiary care centers, safety-net hospitals, and
Veterans Affairs hospitals from 25 states in the United
States. Participating sites were a convenience sample of
academic centers, representing each US region. A single
What You Need to Know
Background
The use and timing of direct acting antivirals (DAAs)
for patients with a history of treated hepatocellular
carcinoma (HCC) is controversial due to concerns
about risk of HCC recurrence.
Findings
In a survey of 279 hepatology practitioners, weprovider at each site, whose email was obtained from 
their institutional Web site, was asked to distribute the 
survey to all hepatology providers at his or her institu-
tion. Eligible providers included physicians (MD/DO) and 
advanced practice providers (APPs) involved in clinical 
care of patients with HCV. We excluded providers who 
primarily treat patients <18 years of age, nonhepatology 
providers, and those with incomplete surveys. The study 
was approved by the institutional review board at the 
University of Texas Southwestern Medical Center.found variation in perceived risk of HCC recurrence
after DAA therapy. Most providers believe DAAs
reduce mortality in patients with a history of com-
plete response to HCC therapy. Recommendations
for DAA therapy in HCC patients varied by tumor
stage, with fewer providers recommending DAAs for
patients with a history of intermediate or advanced
HCC than early HCC. Timing of DAA therapy also
varied among providers, with some starting DAA
around time of HCC treatment and others delaying
DAA for months to confirm complete response to
HCC treatment.
Implications for patient care
Future studies characterizing the risks and benefits
of DAAs for patients with a history of HCC might help
standardize clinical practice for these patients.Survey Information
We distributed an anonymous web-based survey to
eligible hepatology providers between February 1, 2019
and February 28, 2019. We sent a single email reminder
to those who had not completed the survey after 1–2
weeks. The survey had 38 questions and took an average
of 10 minutes to complete.
The content of the survey was based on a conceptual
model, adapted from a previously proposed model of
physician behavior (Figure 1).14 Survey questions were
organized into 5 sections:
1. Provider experience (4 questions): assessed pro-
vider experience with HCV and HCC treatment.
2. Provider practice patterns (7 questions): assessed
provider practice patterns with regard to HCV
treatment, HCC treatment, and HCC surveillance.
3. Clinical vignettes (10 questions): included 4 clin-
ical vignettes to assess provider practices for pa-
tients with different stages of HCC undergoing
curative and palliative HCC treatments.
4. Provider attitudes and beliefs (9 questions):
assessed provider attitudes and beliefs about po-
tential benefits and risks of DAA therapy in pa-
tients with HCC.
5. Provider demographics (8 questions): recorded
provider demographics including age, sex, race/
ethnicity, number of years in clinical practice,provider type (physician vs APP), presence of an
institutional multidisciplinary tumor board, and
number of patients treated annually with HCV and
HCC.
Questions were adapted from validated surveys
when available.15 The survey was pretested among 5
MD providers, at which time saturation of feedback was
believed to have been achieved. Each provider partici-
pated in a cognitive interview after survey completion,
and the survey was iteratively revised based on feed-
back before distribution to study participants. The




Table 1. Provider and Institution Characteristics (n ¼ 279)
Characteristics N (%)
Provider
Sex (% male) 133 (48.4)
Race/ethnicity
Non-Hispanic white 146 (53.3)
Black 4 (1.5)
Hispanic 11 (4.0)
Asian/Pacific Islander 81 (29.6)
Other 32 (11.7)
Type of practitioner





10–20 75 (27.0)Statistical Analysis
Survey responses were summarized using descrip-
tive statistics. The primary outcome of interest was
provider-reported practice patterns for DAA recom-
mendations in patients with HCC, based on provider
responses to 4 clinical vignettes. Secondary outcomes
included provider attitudes regarding the use of DAAs
in patients with HCC. Fisher exact and chi-square tests
were performed for categorical variables to identify
factors associated with DAA recommendation patterns.
Independent variables included provider de-
mographics and perceived DAA benefit in patients with
HCC. Tests were 2-sided and performed at the 5%
significance level. Statistical analysis was performed
using Stata version 14.0 (College Station, TX).>20 48 (17.3)

















Tertiary referral center with transplant program 245 (88.4)
Tertiary referral center without transplant program 8 (2.9)
Veterans Affairs hospital 9 (3.3)
Community-based hospital 7 (2.5)
Safety-net hospital 8 (2.9)
Approximate number of patients with HCC treated at
institution annually
0–50 19 (6.9)Results
Provider and Institutional Characteristics
Of 331 surveys returned, 52 were excluded because
of being incomplete, leaving a total of 279 responses.
This represented a 58.6% (279 of 476) provider-level
and 92.2% (47 of 51) institution-level response rate.
Characteristics of respondents are summarized in
Table 1. Most respondents were MD or DO providers,
over 50% were female, and the sample was racially
and ethnically diverse. Most providers identified their
primary practice location as a tertiary referral center
with a transplant program, approximately three-
fourths had been in practice for >5 years, and nearly
two-thirds spent >75% of time on clinical care. More
than 75% of providers had treated more than 50 total
patients with HCV with DAAs, and 90% reported being
directly involved in HCC management.51–100 57 (20.8)
101–150 58 (21.2)
>150 140 (51.1)
Presence of multidisciplinary HCC clinic and/or
conference (% yes)
274 (98.6)
APP, advanced practice provider; DAA, direct-acting antiviral; DO, Doctor of
Osteopathic Medicine; HCC, hepatocellular carcinoma; HCV, hepatitis C virus;
MD, Medical Doctor.Provider Attitudes Regarding Use of Direct-
Acting Antivirals in Patients With Hepatocellular
Carcinoma
Provider-reported attitudes regarding the use of
DAAs in the setting of HCC are reported in Table 2.
Nearly 80% of providers believed DAAs reduce risk of
incident de novo HCC in patients with cirrhosis.
However, there was wider variation in perceived risk
of HCC recurrence after DAA therapy in patients with
complete response to HCC treatment, with 48%
believing DAAs reduce risk of recurrence, 36%
believing DAAs do not change HCC recurrence risk,
and 16% believing DAAs increase recurrence risk.
Despite this, most still believed DAAs reduce mortal-
ity, are cost-effective, and have overall benefit in pa-
tients with complete response to HCC treatment. In
fact, nearly all providers were likely to recommend
DAAs in patients with a history of HCC, although 50%delayed initiation of DAA therapy by 4–6 months
following HCC complete response. Only 5% of pro-
viders believed HCC recurrence after DAA therapy
could pose legal liability, compared with more than
one-third believing this was possible in untreated
patients who experience hepatic decompensation.
However, 60% of providers reported counseling their
patients regarding the risk of HCC recurrence before
DAA therapy. Overall, 85% of providers believed this
is an area of continued controversy in need of more
data and guidance.
Table 2. Provider Attitudes Regarding Use of DAAs in
Patients With HCC (n ¼ 279)
Provider attitude N (%)
Impact of DAA on incident HCC risk in patients
with cirrhosis
Significant reduction in risk 167 (60.1)
Small reduction in risk 53 (19.1)
No change in risk 41 (14.7)
Small increase in risk 15 (5.4)
Significant increase in risk 2 (0.7)
Impact of DAA on risk of HCC recurrence in patients
with CR to HCC treatment
Significant reduction in risk 46 (16.7)
Small reduction in risk 85 (30.8)
No change in risk 99 (36.0)
No change in risk but shortens time-to-recurrence 15 (5.4)
Small increase in risk 30 (10.9)
Significant increase in risk 0 (0.0)
Impact of DAA on mortality in patients with
CR to HCC treatment
Significant reduction in mortality 104 (37.8)
Small reduction in mortality 110 (40.0)
No change in mortality 56 (20.4)
Small increase in mortality 4 (1.4)
Significant increase in mortality 1 (0.4)
Impact of active HCC on likelihood of achieving
SVR with DAA treatment
Significant reduction in SVR rates 57 (20.4)
Small reduction in SVR rates 114 (40.9)
No change in SVR rates 104 (37.3)
Small increase in SVR rates 4 (1.4)
Significant increase in SVR rates 0 (0.0)
DAAs are cost-effective in patients with
CR to HCC treatment
Strongly agree 114 (40.9)
Agree 151 (54.1)
Disagree 13 (4.7)
Strongly disagree 1 (0.4)
Overall, DAAs are beneficial in patients with
CR to HCC treatment
Strongly agree 133 (47.7)
Agree 139 (49.8)
Disagree 6 (2.1)
Strongly disagree 1 (0.4)
Treating patients with HCC with DAAs may pose legal
liability if patients have HCC recurrence
Strongly agree 2 (0.7)
Agree 15 (5.4)
Disagree 161 (57.7)
Strongly disagree 101 (36.2)
Not treating patients with HCC with DAAs may pose legal
liability if patients develop hepatic decompensation
Strongly agree 27 (9.7)
Agree 80 (28.8)
Disagree 134 (48.2)
Strongly disagree 37 (13.3)
More data and guidance are needed on risk of HCC
recurrence after DAAs
Strongly agree 117 (41.9)
Agree 122 (43.7)
Disagree 35 (12.5)
Strongly disagree 5 (1.8)
Table 2. Continued
Provider attitude N (%)
How have recent studies on DAA and HCC risk
changed your clinical practice?
No longer use DAAs in patients with HCC 0 (0.0)
Less likely to use DAAs in patients with HCC 12 (4.4)
Equally likely to use DAAs but I delay therapy 4–6 mo
after CR
138 (50.6)
Equally likely to use DAAs with no change in my practice 123 (45.0)
Does HCC treatment modality that led to CR impact your
decision regarding timing of DAA?
Yes 64 (23.5)
No 192 (70.6)
Not applicable, I use DAA in patients with active HCC 8 (2.9)
Other 8 (2.9)






Timing of DAA therapy in transplant candidate with HCC
Routinely treat pretransplant on waitlist 15 (5.3)
Case-by-case basis 119 (41.9)
Routinely treat with DAA within 3 mo post-transplant 122 (43.0)
Routinely defer DAA >6 mo post-transplant 298 (9.9)
CR, complete response; DAA, direct-acting antiviral; HCC, hepatocellular
carcinoma; SVR, sustained virologic response.MD and DO providers were significantly more likely
than APPs to believe that DAAs reduce risk of incident HCC
(84.5% vs 66.3%; P¼ .002); however, attitudes about HCC
incidence or recurrence did not otherwise differ by pro-
vider sex, race/ethnicity, years in practice, provider
experience with HCV or HCC treatment, type of institution,
or region of the United States in which they practiced.Provider Attitudes Regarding Hepatocellular
Carcinoma Surveillance After Sustained
Virologic Response
Surveillance practices in patients without a history of
HCC are shown in Table 3. More than 90% of providers
continue to follow post-SVR patients with cirrhosis in
their clinics and perform HCC surveillance with imaging
 a-fetoprotein every 6 months indefinitely. Nearly 95%
reported performing HCC surveillance in some patients
with stage 3 fibrosis (F3), with 61% performing sur-
veillance in all F3 patients.Provider Practices Regarding Use of Direct-
Acting Antivirals in Patients With Hepatocellular
Carcinoma
Provider practice patterns for DAA use and DAA
timing among patients undergoing HCC therapy are
Table 3. HCC Surveillance Practice Patterns in Post-SVR
Patients (n ¼ 279)
Provider practice N (%)
Length of time patients with cirrhosis with SVR
post-DAAs are followed in hepatology clinic
Indefinitely 255 (91.7)
Approx. 1 y then discharge to PCP 9 (3.2)
Approx. 3–5 y then discharge to PCP 6 (2.2)
Not routinely followed; seen as needed 9 (2.9)
Method of HCC surveillance in patients with
cirrhosis after SVR
Imaging (US, CT, or MR)  AFP every 6 mo indefinitely 264 (95.0)
Imaging (US, CT, or MR)  AFP every 12 mo indefinitely 8 (2.9)




Do you perform HCC surveillance in patients




AFP, a-fetoprotein; CT, computed tomography; DAA, direct-acting antivirals;
F3, stage 3 fibrosis; HCC, hepatocellular carcinoma; MR, magnetic resonance
imaging; PCP, primary care physician; SVR, sustained virologic response; US,
ultrasound.illustrated in Figure 2A and Figure 2B, respectively.
Based on the clinical vignettes, the proportion of pro-
viders recommending DAA therapy and timing of such
therapy varied by HCC stage and treatment type. Pro-
viders were significantly less likely to recommend DAAs
in patients with intermediate- or advanced-stage HCC
undergoing palliative treatments than early stage pa-
tients with HCC undergoing curative therapy. Although
nearly 95% would recommend DAAs in a patient with
early stage HCC undergoing surgical resection, this was
reported by only 73% and 57% of providers for
intermediate-stage patients with HCC undergoing trans-
arterial chemoembolization and advanced-stage patients
with HCC undergoing systemic therapy, respectively.
However, providers seemed willing to treat patients with
more advanced HCC if they had a response to HCC-
directed therapies, with nearly 40% willing to treat
advanced-stage patients with HCC if they had an objec-
tive response to treatment. Nearly 70% of providers
reported the modality leading to an HCC complete
response would not impact their likelihood to recom-
mend DAA therapy. Provider responses varied with re-
gard to timing of DAA initiation based on HCC stage and
treatment modality as demonstrated in Table 4. Overall,
15%–20% of providers reported they would initiate DAA
therapy before HCC treatment; however, more than 50%
delayed DAA initiation at least 3 months and 5%–10%
delayed initiation more than 1 year. In patients with HCC
listed for liver transplantation, only 5% of providers
reported routinely treating patients with DAAs while on
the waiting list, with most (53%) treating HCV post-
transplant or on a case-by-case basis (42%).Physicians (MDs and DOs) seemed less likely than
APPs to treat patients with HCC undergoing palliative
therapies; the difference did not reach statistical signifi-
cance for patients undergoing transarterial chemo-
embolization (55.7% vs 62.2%; P ¼ .32) but was
significantly lower in patients undergoing systemic
therapy (68.4% vs 83.1%; P ¼ .01). Providers were also
more likely to recommend DAAs in patients receiving
systemic therapy if they reported fearing potential legal
liability for untreated patients who experience hepatic
decompensation (65.4% vs 52.1%; P ¼ .03). There was
no significant variation in use or timing of DAAs in any
clinical vignettes based on institution type (transplant
center vs other), region, or provider experience (number
of patients treated with HCV or HCC).Discussion
To the best of our knowledge, this study represents
the first nationally representative survey assessing hep-
atology provider attitudes and practice patterns
regarding DAA use in patients with HCC. Although there
was variation in provider beliefs regarding HCC recur-
rence risk after DAA therapy, we found that most still
believed DAAs are beneficial and likely reduce mortality
in patients with complete response to HCC treatment.
Accordingly, nearly all providers reported recommend-
ing DAA therapy in patients with early HCC undergoing
curative treatment; however, fewer providers recom-
mended DAA therapy in those with intermediate- or
advanced-stage HCC undergoing palliative therapies.
In contrast to the strong data showing reduced risk of
incident de novo HCC after DAA therapy,7–9 there are
conflicting data about HCC recurrence risk after DAA
therapy in patients with a history of HCC. Although data
from a multicenter cohort in North America suggested no
difference in recurrence risk between DAA-treated and
untreated patients,11 most studies share similar notable
limitations: retrospective study design, heterogeneity of
tumor burden and treatment leading to complete
response, potential for misclassification of complete
response, and ascertainment bias for recurrence given
lack of a surveillance protocol. Therefore, there is a lack
of consensus among professional society guidance
statements regarding timing of DAA therapy in patients
with a history of HCC. The American Association for the
Study of Liver Diseases practice guidance recommends
DAA therapy after 3–6 months if no evidence of recur-
rence,16 whereas an American Gastroenterological As-
sociation clinical practice update highlights a lack of
sufficient data to determine if there is increased or
decreased recurrence risk,17 and the European Associa-
tion for the Study of the Liver guidelines state that it
remains unclear if DAA therapy increases recurrence but
advises caution in this population.18 This is reflected in
the variation in perceived risk of HCC recurrence after
DAA therapy among providers in our survey. However,
Figure 2. (A) Provider
practice patterns for DAA
treatment in patients with
HCC, according to HCC
treatment. (B) Provider
practice patterns for
timing of DAA treatment in
patients with HCC, ac-
cording to HCC treatment.
CR, complete response;
TACE, transarterial
chemoembolization.most providers still believed that DAA therapy would be
of overall benefit in patients with HCC. This may be
caused, in part, by beliefs that DAAs have a favorable side
effect profile or by strong patient preference for viral
eradication. Independent of recurrence risk, DAA therapy
may improve liver dysfunction and thereby reduce
mortality. In fact, hepatic decompensation, not HCC
recurrence, is the major driver of mortality in patients
with a history of HCC who achieved complete response.19
Recent data suggest DAAs may reduce hepatic decom-
pensation and improve overall survival among patients
with early stage HCC who achieved complete responsefrom resection or ablation.20 These evolving data suggest
that patients with confirmed HCC complete response
likely benefit from DAA therapy, although further data
with larger sample sizes and more heterogeneous tumor
burden are needed to confirm the potential benefit of
DAA therapy against the competing risk of liver-related
mortality on overall survival.
Provider recommendations for DAA therapy differed
by HCC stage and treatment type, with providers being
less likely to recommend DAAs in advanced patients with
HCC undergoing palliative treatments than in early stage
patients undergoing curative therapy. This variation is
Table 4. Timing of DAA Therapy Initiation in Patients With
HCC, Stratified by HCC Treatment (n ¼ 279)
Provider practice N (%)
Timing of DAA initiation in patient with BCLC stage A
HCC undergoing surgical resection
Shortly after resection (before imaging showing CR) 52 (18.8)
<3 mo after CR 84 (30.3)
3–6 mo after CR 41 (14.8)
6–12 mo after CR 86 (31.1)
>12 mo after CR 14 (5.0)
Timing of DAA in patient with BCLC stage B HCC
undergoing TACE
Shortly after TACE (before imaging showing CR) 47 (17.2)
<3 mo after CR 68 (24.8)
3–6 mo after CR 41 (15.0)
6–12 mo after CR 87 (31.7)
>12 mo after CR 31 (11.3)
Timing of DAA in patient with BCLC stage C HCC
undergoing systemic therapy
Begin DAA at time of initiating systemic therapy 27 (9.8)
Start DAA if partial response 34 (12.4)
Start DAA if complete response 78 (28.4)
Would start DAA if develops liver dysfunction, even if
active HCC
19 (6.9)
Would never start DAA 117 (42.5)
Timing of DAA therapy in liver transplant candidate with
HCC
Routinely treat pretransplant on waitlist 15 (5.5)
Case-by-case basis 115 (42.0)
Routinely treat with DAA within 3 mo post-transplant 118 (43.0)
Routinely defer DAA >6 mo post-transplant 26 (9.5)
BCLC, Barcelona Clinic Liver Cancer; CR, complete response; DAA, direct-
acting antiviral; HCC, hepatocellular carcinoma; TACE, transarterial
chemoembolization.presumably driven by the perceived likelihood of
achieving a complete response to HCC therapy and the
competing risk of HCC-related mortality in patients with
more advanced HCC. However, it is possible that DAA
therapy in patients with intermediate- or advanced-stage
HCC may still be beneficial as expected survival for these
patients continues to improve. For example, the median
survival for Child Pugh A patients with intermediate
stage HCC is approaching 3 years,21,22 whereas median
survival for advanced-stage patients with HCC is also
improving with new systemic options in first- and
second-line settings.23,24 Prior small studies have sug-
gested patients with HCC who have achieved SVR have
improved prognosis compared with those with active
viremia.25 The reported variation in practice observed
may also have been driven by prior reports of lower SVR
rates in patients with active HCC.12,13 In fact, nearly two-
thirds of providers raised this concern in patients with
active HCC. The American Association for the Study of
Liver Diseases practice guidance for HCV therapy rec-
ommends consideration of DAA therapy in patients with
expected survival exceeding 1 year, raising the question
if this should be considered in patients with intermediate
and advanced HCC.26 As we aim for HCV elimination in
all populations, this remains 1 of the few subgroups in
whom the benefit of DAA treatment remains unclear.We observed variation in timing of DAA initiation for
all HCC treatment modalities, with some providers
treating HCV shortly after HCC complete response and
others deferring for several months. We did not find any
factor associated with timing of DAA therapy, including a
lack of association with provider type, years in practice,
or geographic region; this variation may reflect provider
knowledge and attitudes that were not included in our
survey. There are conflicting data about the importance
of DAA timing when considering HCC recurrence risk.
Some studies have reported increased recurrence risk
with early DAA treatment after HCC complete response
when compared with deferred DAA treatment; however,
this finding has not been replicated in subsequent
studies.10,11 An American Gastroenterological Associa-
tion clinical practice update recommends deferring DAA
therapy for 4–6 months following HCC treatment based
on the importance of confirming complete response
rather than a concern about increasing HCC recurrence
risk.17 Given the imperfect sensitivity of imaging to
detect small HCC lesions and the nonurgent nature of
HCV therapy, this seems like a reasonable approach for
timing of DAA therapy after HCC complete response.
The important consideration of DAA timing in the
context of liver transplantation may have influenced
provider responses to the survey. More than half of the
providers reported their practice is to routinely delay
HCV treatment until the post-transplant period in pa-
tients with HCC (who may be undergoing locoregional
therapy). This strategy allows for expansion of the donor
pool by increasing use of organs from HCV-positive do-
nors, in light of data showing excellent graft and overall
survival.27 This may have produced variation in practice
patterns for the patient undergoing locoregional therapy
in the second clinical vignette. Although our intent was to
present a patient beyond Milan Criteria, some re-
spondents may have deferred HCV therapy with down-
staging and transplantation in mind.
Lastly, our study addressed patterns of HCC surveil-
lance after DAA treatment and subsequent SVR. Although
risk of incident HCC is reduced following HCV cure, it is
not zero and a proportion of patients will still develop
HCC.28 Thus, continued surveillance is recommended in
all patients with HCV cirrhosis even after SVR. Almost all
providers in our study reported continuing surveillance
with imaging  a-fetoprotein every 6 months in patients
with cirrhosis. Interestingly, 95% also reported per-
forming surveillance in at least some patients with F3
fibrosis after SVR, with more than 60% performing sur-
veillance in all F3 patients. Kanwal et al9 demonstrated
the risk of HCC is very low (w0.1%) in patients without
cirrhosis except for those with Fib-4 >3.25 (indicating
advanced fibrosis), where the annual risk approaches
1%, calling into question the benefit and cost-
effectiveness of surveillance in patients with F3 fibrosis
after SVR.29 Notably, some patients labeled as having F3
fibrosis may be misclassified and truly have cirrhosis,
suggesting surveillance may be needed in selected
patients. Predictive models may be useful to identify 
patients with F3 fibrosis at highest risk of HCC after SVR 
who could benefit from HCC surveillance.30
Strengths of this study include its large sample size 
and high response rate; however, we acknowledge that 
our study has limitations. First, the survey was distrib-
uted using a convenience sample of tertiary academic 
centers, with >98% having multidisciplinary tumor 
boards, which may limit generalizability to other practice 
settings, including community practices, safety-net 
health systems, and Veterans Affairs hospitals. Howev-
er, we attempted to mitigate this concern by sampling 
sites from various US regions and including different 
provider types (MD/DOs and APPs). Second, the survey 
was performed and reflects practice patterns in the 
United States, which may differ from approaches in 
Europe and Asia. Third, nonhepatology providers 
involved in HCV treatment, including infectious disease 
and internal medicine providers, were not included in 
our sampling frame. Fourth, our results may be limited 
by response bias, in which providers report how they 
should practice rather than their actual practice; and 
nonresponse bias, in which providers who feel more 
comfortable managing HCV and HCC may be more likely 
to respond. Fifth, decisions and timing of HCV and HCC 
treatment are often considered in the context of trans-
plant candidacy, which was not explicitly addressed in 
some cases and may have influenced provider responses. 
Similarly, other details that were not explicitly addressed 
may have impacted providers’ interpretation of the 
clinical vignettes, and thereby explain some observed 
variation in provider responses. Sixth, we did not 
address patient preferences (regarding HCV treatment, 
HCC treatment, and/or transplantation), which play an 
important role in shared decision-making. Finally, the 
previously discussed limitations highlight the complexity 
of decisions about timing of HCV treatment in patients 
with HCC, thus all potential management options may 
not have been available for some questions.
In conclusion, in this nationwide survey study of 
hepatology providers, we found variation in attitudes 
and practice patterns regarding the use of DAAs in pa-
tients with HCC. Our findings highlight a need for high-
quality data characterizing the risks and benefits of 
DAA therapy in patients with a history of HCC after 
complete response and those with active HCC. These data 
can inform guideline recommendations to help improve 
and standardize clinical practice for patients with HCV 
and HCC.Supplementary Material
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